Sort by
Refine Your Search
-
possibility of extension for teaching activities. About SURE-AI SURE-AI is a Norwegian AI centre funded by the Research Council of Norway (2025-2030). The primary objective is to create a new generation of
-
partners. The primary objective of MishMash is to create, explore, and reflect on AI for, through, and in creative practices. MishMash researchers will investigate AI’s impact on creative processes, develop
-
disintegrative effects of blockades with regard to markets, wartime societies and the international order. The team members will work together across locations to build a rich primary source base for BLOCKADE
-
funded by the Research Council of Norway (2025-2030). The primary objective is to create a new generation of algorithms for inference and decision-making by pushing the boundaries of the underlying
-
consulted by the candidates. The position encompasses possibilities for teaching tasks within TIK’s bachelor teaching and master programs, including supervision of students within these programs, according
-
teaching and master programs, including supervision of students within these programs, according to the TIK Centre’s needs and the candidate’s profile or competencies. If such tasks are agreed upon
-
plasmid preparation, retroviral transduction of T cells, culture of primary T cells, multiparameter (up to 12 colors) flow cytometry assays including functional T-cell assays (cytokine release, cytotoxicity
-
the original language. An English translation of these documents must also be attached. Contact information for 2-3 references. One of them must be a PhD supervisor. Also preferably including the supervisors
-
work experience (CV) Witnessed copies of diplomas and relevant certificates (applicants with education from other countries than Norway must enclose diplomas in both the original language and authorized
-
at European Palliative Care Research Centre (PRC) Apply for this job See advertisement About the position For a clinical researcher with a primary position at the Department of Oncology, Oslo University